SCHEDULE 13D/A: Celadon Partners Amends Senti Biosciences Stake Disclosure, Clarifying Management Details

Celadon Partners SPV 24 and Celadon Partners, LLC filed an Amendment No. 1 to their Schedule 13D for Senti Biosciences, Inc., solely to provide detailed information on their managers.

Summary

• Celadon Partners SPV 24 and Celadon Partners, LLC filed Amendment No. 1 to their Schedule 13D regarding their beneficial ownership in Senti Biosciences, Inc.
• The amendment's sole purpose is to provide Appendix A, which details the names, business addresses, citizenship, and principal occupations of the managers of Celadon Partners SPV 24 and Celadon Partners, LLC.
• No other information from the original Schedule 13D, filed on March 13, 2025, has been amended.
• Celadon Partners SPV 24 and Celadon Partners, LLC collectively beneficially own 9,777,000 shares of Senti Biosciences, Inc. Common Stock.
• This ownership represents 37.6% of the class of Senti Biosciences, Inc. Common Stock.

Sentiment

Score: 5

Explanation: The document is neutral in sentiment as it is a routine regulatory filing providing additional factual details about a significant shareholder, rather than reporting on operational performance or strategic changes.

Positives

• Increased transparency regarding the management structure and individuals behind the significant shareholder, Celadon Partners SPV 24 and Celadon Partners, LLC, through the disclosure of Appendix A.

Risks

• No new risks to Senti Biosciences, Inc. were introduced or highlighted by this amendment, as its purpose was solely to provide additional detail on the reporting persons.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Senti Biosciences, Inc.'s future operations or financial performance.

Management Comments

• David Egglishaw, Manager of Celadon Partners, LLC (as sole manager of Celadon Partners SPV 24), certified that the information set forth in the statement is true, complete, and correct to the best of his knowledge and belief.

Industry Context

This filing is a routine regulatory disclosure related to significant share ownership and does not provide specific insights into broader industry trends or Senti Biosciences' competitive position within the biotechnology sector.

Stakeholder Impact

• Shareholders: Provides increased transparency regarding the individuals managing the significant shareholding entity, Celadon Partners, which may offer a clearer understanding of the ownership structure.

Key Dates

Keywords

Senti Biosciences, Celadon Partners, Schedule 13D, SEC filing, beneficial ownership, biotechnology, disclosure, corporate governance